Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
| Autor: | Scott Fung, Belinda Jump, Sang Hoon Ahn, William Guyer, Giovanni Battista Gaeta, Henry Lik-Yuen Chan, Magdy Elkhashab, Gerald Crans, Won Young Tak, Xiaoli Ma, Florin Alexandru Caruntu, Fehmi Tabak, Jörg Petersen, Wan-Long Chuang, Mani Subramanian, R. Mehta, Aric J. Hui, Patrick Marcellin, Alain Chan, Maria Buti, Robert Flisiak, George V. Papatheodoridis |
|---|---|
| Přispěvatelé: | Ahn, Sang Hoon, Marcellin, Patrick, Ma, Xiaoli, Caruntu, Florin A, Tak, Won Young, Elkhashab, Magdy, Chuang, Wan-Long, Tabak, Fehmi, Mehta, Rajiv, Petersen, Jörg, Guyer, William, Jump, Belinda, Chan, Alain, Subramanian, Mani, Crans, Gerald, Fung, Scott, Buti, Maria, Gaeta, Giovanni B, Hui, Aric J, Papatheodoridis, George, Flisiak, Robert, Chan, Henry L Y |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty HBsAg Physiology Chronic hepatitis B Gastroenterology Group A Group B 03 medical and health sciences 0302 clinical medicine Pegylated interferon Internal medicine medicine HBsAg seroconversion Seroconversion business.industry Virological response Hepatology HBsAg lo 3. Good health Discontinuation HBsAg loss 030104 developmental biology Original Article 030211 gastroenterology & hepatology business Peginterferon alfa-2a medicine.drug |
| Zdroj: | Digestive Diseases and Sciences |
| ISSN: | 1573-2568 0163-2116 |
| DOI: | 10.1007/s10620-018-5251-9 |
| Popis: | Background and Aims Hepatitis B surface antigen (HBsAg) loss is the ideal clinical endpoint but is achieved rarely during oral antiviral treatment. A current unmet need in CHB management is achievement of HBsAg loss with a finite course of oral antiviral therapy, thereby allowing discontinuation of treatment. Significantly higher rates of HBsAg loss at 72 weeks post-treatment have been demonstrated when tenofovir disoproxil fumarate (TDF) was combined with pegylated interferon (PEG-IFN) for 48 weeks compared with either monotherapy. This analysis provides follow-up data at week 120. Methods In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus PEG-IFN for 48 weeks (group A), TDF plus PEG-IFN for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or PEG-IFN for 48 weeks (group D). Efficacy and safety at week 120 were assessed. Results Rates of HBsAg loss at week 120 were significantly higher in group A (10.4%) than in group B (3.5%), group C (0%), and group D (3.5%). Rates of HBsAg loss and HBsAg seroconversion in group A were significantly higher than rates in group C (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink